Remember the Saturdays of our childhoods, when hours were forever, and the day was interminable? When our young worlds turned so slowly that super cool ideas for the day became passé by lunch, leaving us facing a void of unexpected idleness? What did we do with all that extra time? We probably spent it trying […]
CONCERTO trial is seeking participants to evaluate the new SING IMT Long-time members of our AMD community may remember FDA approval in 2010 of a unique device called Implantable Miniature Telescope (IMT). Our ensuing write-up described the device as a micro-sized precision telescope which provides magnification of up to 3 times and a 20º field […]
Treatments for neovascularization in the retina may be reduced to as few as two to four times per year. New anti-VEGF drug therapies are now available for treatment of macular diseases. Over the past two years the U.S. Food and Drug Administration (FDA) has approved less invasive, less burdensome, and lower cost drugs and procedures. […]
What makes us angry? As visually impaired and blind senior adults, we often find ourselves metaphorically seeing red when confronted by life without our most dominant sense. We are angered by our loss of independence, our inability to fight injustices, and by the ignorance or indifference of others. Since most of us hale […]
Biogen Inc. and Samsung Bioepis Co., Ltd. has announced that BYOOVIZ™ (ranibizumab-nuna), a biosimilar of LUCENTIS® (ranibizumab) has been launched in the U.S. and will be commercially available on July 1, 2022. The list price will be $1,130 per injection, which is 40% lower than the current list price of LUCENTIS. The FDA approved BYOOVIZ […]